drugset / Trial / NCT01315210

D-Ribose for Fatigue in Subjects With Fibromyalgia

NCT01315210

Phase 2 Completed 110 enrolled RiboCor, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To evaluate the safety and to determine the efficacy of D-ribose for the amelioration of fatigue in subjects with fibromyalgia. This is a phase IIa, randomized, double-blind, placebo-controlled, multi-center, multiple dose study of D-ribose versus placebo administered at doses of 5 g three times a day (TID) over a 12-week period to subjects who are experiencing fatigue associated with a diagnosis of fibromyalgia.

Timeline

Start
2011-05
Primary completion
2012-10
Completion
2012-10

Drugs

EvaluationDrugModalityDoseRoute
Subject RIBOSE (PYRANOSE) Small molecule 5 g

Indications